A new, simple, non-invasive test that predicts risk for cardiovascular disease is to be made available by Gulf & Word Traders throughout the United Arab Emirates and neighboring countries.
A new test developed by an Ann Arbor company that detects people who may be at risk for cardiovascular disease but don’t show symptoms is being launched in Europe at the Healthcare Innovation Expo 2013.
Everist Genomics, a developer of personalized medicine, announced the publication of positive results from an international validation study which demonstrated that the OncoDefender-CRC colorectal cancer test result is a significant independent predictor of recurrence in node-negative, invasive colorectal cancer patients.
Everist Genomics, a rapidly growing personalized medicine company, announced that it has established a joint-venture company with the Manipal Group, a health care company in India. The joint venture will market EGI’s portfolio of diagnostic, prognostic and therapeutic selection technologies in India.
Everist Genomics, a rapidly growing personalized medicine company, today announced the launch of the world’s first comprehensive companion diagnostics and prognostics portfolio to improve early diagnosis, management and treatment of patients with colorectal cancer.
Everist Genomics, a rapidly growing personalized medicine company, today announced that world-renowned scientist and genome sequencing pioneer J. Craig Venter will be the keynote speaker for its March 26th Gala Dinner at the Field Museum in Chicago.
Everist Genomics announced Friday that its executive vice chairman, Alex Charlton, will speak about its breakthrough CardioDefender Device at the Wearable Technologies Conference Monday in Munich, Germany.
The pharma startup Everist Genomics said Tuesday it had identified five specific genes and gene expression levels that lead to recurrence of colorectal cancer — even when the cancer is caught at an early stage and surgically removed.
The medical device startup Everist Genomics Wednesday announced plans to commercialize its CardioDefender diagnostic system.
Everest Genomics announced Monday it has completed the acquisition of 100 percent of the shares of Mountain View, Calif.-based Angiologix Inc., developer of the AngioDefender device for diagnosing heart and vein disease.